Newsroom > In the News
In the news
News headlines are articles that reference ResMed's company, people, or business practices.
S+, Setting a New Standard in Consumer and Clinical Sleep Technology: Interview with Colin Lawlor, CEO of SleepScore LabsMay 3, 2017Medgadget
The S+ platform is the newest technology disrupting the $60B consumer sleep industry. Developed by SleepScore Labs, a joint venture between ResMed, a 25-year leader in prescription sleep medical devices, Dr. Mehmet Oz, and Pegasus Capital Advisors, the S+ is a clinical grade, non-prescription, non-contact sleep monitoring device coupled with a mobile app.
April 25, 2017San Diego Union-Tribune
Instead of packing up their larger, bedside machines from home for a trip, sleep apnea patients can travel with a much smaller device, according to the company. It’s akin to taking a tablet on the road while leaving the desktop computer at home, said ResMed Chief Executive Michael “Mick” Farrell.
April 25, 2017Xconomy
The debut of ResMed’s AirMini is only part of a bigger picture, according to Jim Hollingshead, ResMed’s president of the Americas. Hollingshead said the AirMini is part of a strategic shift that began four or five years ago, when ResMed began to pivot from developing medtech hardware to becoming a provider of “connected healthcare.”
April 13, 2017HME Business
Individuals with obstructive sleep apnea who develop central sleep apnea (CSA) are more compliant with their therapy after switching from continuous positive airway pressure (CPAP) therapy to adaptive servo-ventilation (ASV) therapy, according to a broad survey of sleep patients patients with treatment-emergent CSA that was commissioned by sleep equipment maker ResMed.
April 10, 2017FeibusTech
Mike Feibus tries S+, the world's first non-contact sleep tracker, discusses what it does, what it has, and more.
April 4, 2017American Thoracic Society
The American Thoracic Society today announced a new $100,000 two-year research fellowship funded by ResMed in the area of noninvasive ventilation (NIV) in chronic obstructive pulmonary disease (COPD).
March 23, 2017Mergers & Acquisitions
“Brightree was an important and immediately accretive strategic acquisition for ResMed. It exemplified a double-down on our ongoing investments to leverage connected care and digital health, and to change the basis of competition in our industry,” ResMed CEO Mick Farrell told Mergers & Acquisitions in a March 2017 interview. “One year from announcing the acquisition, we can reaffirm our goals going in: Brightree represents a big step forward for ResMed, fulfilling our role as the world’s leading tech-driven medical device company, liberating data and unlocking incredible value for our customers.”
March 21, 2017Crain's San Diego
The toughest moments are the ones that contribute most to developing strength and leadership. That point came for me in Lyon, France, early in my tenure as CEO. I had been on a round-the-world business trip that spanned seven countries in 14 days. It was Sunday morning, and I had gone for a run and had just had a lovely lunch, but when I returned to my hotel room, I suddenly felt deathly lonely.
March 3, 2017Dossier, Hemispheres by United Airlines (see page 8)
“If [ResMed] still can be known as the world leader in respiratory medicine, that’s great, but if we can be known as the world’s leading tech-driven medical device company, that liberated data and inspired people in other disease states beyond sleep apnea and COPD to do so, we’ll really get there,” says CEO Mick Farrell.
March 3, 2017Medical Device and Diagnostic Industry
ResMed Healthcare Informatics Director Amy Cook details ResMed’s plan to improve CPAP device use and encourage compliance in her talk “Mission Impossible—Making a CPAP that Users Won’t Abandon” at the MD&M West 2017 conference.